Technical Analysis for ADXS - Advaxis, Inc.

Grade Last Price % Change Price Change
grade F 0.2977 -3.19% -0.01
ADXS closed down 3.19 percent on Monday, September 16, 2019, on 1.51 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical ADXS trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Narrow Range Bar Range Contraction -3.19%
Inside Day Range Contraction -3.19%
Wide Bands Range Expansion -3.19%
Wide Bands Range Expansion -0.77%
Lower Bollinger Band Touch Weakness -0.77%
Volume Surge Other -0.77%
Wide Bands Range Expansion -0.77%

Older signals for ADXS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The company's platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. It has approximately 15 distinct constructs in various stages of development, directly developed by the company and through strategic collaborations. The company's products in clinical development stage include ADXS-HPV that is being evaluated in clinical trials for cervical cancer, CIN 2/3, head and neck cancer, and anal cancer. Its products in clinical development stage also comprise ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company was founded in 2002 and is based in Princeton, New Jersey.
Medicine Biotechnology Cancer Infectious Diseases Cancers Prostate Cancer Tumor Immunotherapies Infectious Causes Of Cancer Platform Technology Head And Neck Cancer Cancer Vaccine Human Papillomavirus Infection Osteosarcoma Cervical Cancer Anal Cancer
Is ADXS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.55
52 Week Low 0.26
Average Volume 1,072,437
200-Day Moving Average 3.432
50-Day Moving Average 0.6513
20-Day Moving Average 0.3452
10-Day Moving Average 0.3149
Average True Range 0.0522
ADX 55.92
+DI 9.7089
-DI 32.8756
Chandelier Exit (Long, 3 ATRs ) 0.2934
Chandelier Exit (Short, 3 ATRs ) 0.4166
Upper Bollinger Band 0.4254
Lower Bollinger Band 0.265
Percent B (%b) 0.2
BandWidth 46.465817
MACD Line -0.1058
MACD Signal Line -0.134
MACD Histogram 0.0283
Fundamentals Value
Market Cap 12.23 Million
Num Shares 41.1 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.13
Price-to-Sales 9.06
Price-to-Book 1.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.33
Resistance 3 (R3) 0.33 0.32 0.33
Resistance 2 (R2) 0.32 0.32 0.32 0.32
Resistance 1 (R1) 0.31 0.31 0.31 0.31 0.32
Pivot Point 0.30 0.30 0.30 0.30 0.30
Support 1 (S1) 0.29 0.29 0.28 0.29 0.27
Support 2 (S2) 0.28 0.29 0.28 0.27
Support 3 (S3) 0.27 0.28 0.27
Support 4 (S4) 0.26